Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioFem Vag
- Development stage
- Unknown
- Lead developer
- Takgene
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
BioFem Vag (also referred to as BioFemVage) is a vaginal probiotic capsule developed and marketed by Takgene Pharma. It contains the probiotic bacterium *Lactobacillus plantarum* at a strength of 1×10^9 CFU per capsule. The product is designed to restore and maintain the natural vaginal microflora, particularly after antibiotic therapy, and to prevent recurrent bacterial vaginosis and vulvovaginal candidiasis. *Lactobacillus plantarum* colonizes the vaginal epithelium, lowering vaginal pH through the production of organic acids (such as lactic acid) and producing antimicrobial compounds like hydrogen peroxide and bacteriocins, thereby inhibiting the growth and biofilm formation of pathogens like *Gardnerella vaginalis* and *Candida* species.
- Brand names
- BioFem VagBioFemVage
- Other names
- بایوفم واژ
Beyond the preview
Go deeper on BioFem Vag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioFem Vag.